Comparative Pharmacology
Head-to-head clinical analysis: HYDROMOX versus INDERIDE LA 80 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROMOX versus INDERIDE LA 80 50.
HYDROMOX vs INDERIDE LA 80/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion.
Combination of propranolol (non-selective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water, reducing plasma volume.
50-100 mg orally once daily; may increase to 200 mg/day for severe edema.
One capsule orally once daily, containing propranolol hydrochloride 80 mg (immediate release) and hydrochlorothiazide 50 mg. May be titrated based on response, with maximum propranolol dose 640 mg/day and maximum hydrochlorothiazide dose 50 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6-9 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Propranolol: 3-6 hours (poor metabolizers up to 10 hours). Hydrochlorthiazide: 6-15 hours (prolonged in renal impairment).
Renal: 70% unchanged via tubular secretion; biliary/fecal: <10%
Renal elimination of propranolol and hydrochlorthiazide: propranolol is extensively metabolized in the liver, <1% excreted unchanged in urine; hydrochlorthiazide is excreted unchanged in urine (≥95% renal).
Category C
Category C
Thiazide Diuretic
Beta Blocker and Thiazide Diuretic